Clinical Trial Update: Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of eribulin in angiosarcoma and epithelioid hemangioendothelioma has posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma
• Epithelioid Hemangioendothelioma

Drugs mentioned

• Halaven (eribulin mesylate) (eribulin mesylate)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Angiosarcoma, Epithelioid Hemangioendothelioma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-11-08